Ike Stewart, MD
Family Medicine · Sumter, SCNPI 1255340329
Payments from drug & device makers
Across 288 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$603
- AstraZeneca$477
- Amgen$295
- Pfizer$294
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$290
- Novo Nordisk$260
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,112100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $603 |
| AstraZeneca | 34 | $477 |
| Amgen | 18 | $295 |
| Pfizer | 21 | $294 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $290 |
| Novo Nordisk | 19 | $260 |
| Lilly USA, LLC | 22 | $257 |
| Boehringer Ingelheim | 12 | $200 |
| Sanofi-aventis U.S. LLC | 9 | $151 |
| GSK | 11 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $106 |
| Kowa Pharmaceuticals America, Inc. | 8 | $102 |
| Abbott | 6 | $99 |
| Eisai Inc. | 6 | $97 |
| Merck | 7 | $96 |
| Novartis | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Insulet Corporation | 1 | $49 |
| Amarin Pharma, Inc. | 3 | $45 |
| Edwards Lifesciences | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Bayer | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $32 |
| Johnson & Johnson | 2 | $31 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $11 |
How this compares
$4,113 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 134 | $107,208 |
| EliquisApixaban | 108 | $92,488 |
| JardianceEmpagliflozin | 118 | $91,347 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $64,995 |
| LinzessLinaclotide | 62 | $63,271 |
| OzempicSemaglutide | 54 | $58,154 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 81 | $53,361 |
| MounjaroTirzepatide | 42 | $44,131 |
| TrulicityDulaglutide | 30 | $37,813 |
| XareltoRivaroxaban | 42 | $37,616 |
| FarxigaDapagliflozin Propanediol | 43 | $36,395 |
| TradjentaLinagliptin | 24 | $24,026 |
| WegovySemaglutide | 15 | $19,182 |
| MyrbetriqMirabegron | 28 | $18,715 |
| Spiriva RespimatTiotropium Bromide | 29 | $15,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $96 | $160,568215 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $200 | $131,073171 claims |
| PfizerEliquis | $294 | $92,488108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $257 | $81,94472 claims |
| Novo NordiskOzempic, Wegovy | $260 | $77,33669 claims |
| GSKTrelegy Ellipta | $146 | $64,99566 claims |
| AbbVieLinzess | $603 | $63,27162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Qtern, Crestor | $477 | $55,01580 claims |
| Johnson & JohnsonXarelto | $31 | $37,61642 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $21 | $8,05634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Sumter
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.